About Convert Pharmaceuticals

About company

Convert Pharmaceuticals is a preclinical stage drug development company, that is building a proprietary drug pipeline exploiting tumor microenvironment specific factors for therapeutic benefit.Convert’s lead product is a hypoxia activated prodrug (HAP). Hypoxia constitutes a therapeutic obstacle as it promotes the development of resistance to conventional anti-cancer treatments. Convert Pharmaceuticals combines proprietary insights in the tumor microenvironment with expertise in drug and biomarker development to develop effective and well-tolerated HAPs.